Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)
Status:
Completed
Trial end date:
2017-01-08
Target enrollment:
Participant gender:
Summary
Transverse myelitis (TM) is an inflammatory disorder of the spinal cord that leads to
disabilities of gait. Dalfampridine, a sustained-release potassium inhibitor has been shown
to be effective in improving gait and other neurologic functions in multiple sclerosis.
Dalfampridine has the potential to improve neurologic function in patients with transverse
myelitis as this rare disorder shares a similar pathogenic process with multiple sclerosis.
The in a clinical trial to test the efficacy of dalfampridine in TM.
The clinical trial that the investigators propose to conduct will focus on TM and will
evaluate the dalfampridine in primary neurologic outcome, 25-foot timed walk, and several
secondary outcomes including valid behavioral and neurophysiological tests.
This is a re-launch of the previous trial, which now includes additional behavioral and
clinical testing.